Rigel Pharmaceuticals Reports Q1 Revenue Miss, Eli Lilly Terminates Collaboration
RIGL sits 63% above its 52-week low of $16.88.
Summary
Rigel Pharmaceuticals announced first-quarter financial results below analyst expectations and a year-over-year decline in net income, compounded by the termination of a collaboration agreement with Eli Lilly for a key pipeline asset.
Key Events · Earnings and Guidance · RIGL
-
Q1 Financial Results Below Estimates
Rigel reported Q1 2026 total revenues of $58.8 million, falling short of analyst estimates of $62.39 million, and net income of $8.7 million, down from $11.4 million in Q1 2025.
-
Eli Lilly Terminates Collaboration Agreement
Eli Lilly and Company notified Rigel of the termination of their collaboration agreement for ocadusertib (a RIPK1 inhibitor), effective June 15, 2026, impacting a pipeline asset.
-
Debt Facility Restructured
The company restructured its credit relationship, replacing an existing term loan with a new $40.0 million revolving credit facility (with an option to increase to $60.0 million), repaying the remaining $40.0 million term loan and drawing $8.0 million on the new facility.
-
2026 Financial Outlook Reaffirmed
Rigel reaffirmed its full-year 2026 total revenue guidance of $275 million to $290 million and anticipates reporting positive net income for the full year.
Analysis · RIGL · Life Sciences
Rigel's first-quarter results indicate a financial setback with revenues missing analyst expectations and a decline in net income compared to the prior year. More significantly, the termination of the collaboration with Eli Lilly for ocadusertib represents a loss of a pipeline asset and potential future revenue, which is a material negative for a biotechnology company. While the company restructured its debt for increased financial flexibility and reaffirmed its full-year guidance, the immediate impact of the revenue miss and the collaboration termination creates a negative outlook. Investors should monitor the company's ability to meet its reaffirmed guidance and the impact of the collaboration termination on its long-term pipeline strategy.
At the time of this filing, RIGL was trading at $27.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $519.1M. The 52-week trading range was $16.88 to $52.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.